NEW YORK (GenomeWeb News) – AXA Diagnostics will distribute Rosetta Genomics' microRNA-based miRview line of molecular diagnostic cancer tests in Italy, Rosetta said today.
The exclusive distribution agreement with the Pomezia, Italy-based AXA Diagnostics covers the miRview mets, miRview squamous, and miRview meso tests. AXA will market the tests in Italy, and the samples will be analyzed at Rosetta Genomics' CLIA-certified lab in Philadelphia.
Rosetta Genomics' mets test is used to identify primary tumor site in patients with metastatic cancer and in those with cancer of unknown primary origin. The squamous test differentiates squamous from non-squamous, non-small cell lung cancer patients, and the meso test uses biomarkers to differentiate mesothelioma from other lung carcinomas.
Financial terms of the collaboration were not disclosed.